about
Activating HER2 mutations in HER2 gene amplification negative breast cancerHER2 activating mutations are targets for colorectal cancer treatmentStatistically identifying tumor suppressors and oncogenes from pan-cancer genome-sequencing dataTissue phosphoproteomics with PolyMAC identifies potential therapeutic targets in a transgenic mouse model of HER2 positive breast cancer.Anesthesia awareness and the bispectral index.Taspase1-dependent TFIIA cleavage coordinates head morphogenesis by limiting Cdkn2a locus transcription.Long-term cognitive decline in older subjects was not attributable to noncardiac surgery or major illness.Simultaneous quantitative susceptibility mapping (QSM) and R2* for high iron concentration quantification with 3D ultrashort echo time sequences: An echo dependence study.Yet more evidence that myelin protons can be directly imaged with UTE sequences on a clinical 3T scanner: Bicomponent T2* analysis of native and deuterated ovine brain specimens.Interpretive Differences Between Patients and Radiologists Regarding the Diagnostic Confidence Associated With Commonly Used Phrases in the Radiology Report.
P50
Q27851987-30BB26DC-9486-4828-863C-52F1517756EAQ27853193-286FD46D-0163-4740-9AE2-63FC2B307FF2Q30982579-0C2C22F5-C1C8-4795-9325-952A7D3BCD97Q34323926-AA91F253-CC22-4856-BCD5-02B53AE94BBCQ34761281-D6F0894D-4389-42F7-BF0C-AA598C7154B3Q35183840-01A3EF57-BBA0-4603-8973-3F95E5B8167EQ37441445-53D11C95-E532-41B3-AB3B-5221E95ECD1FQ47190958-557ADE8A-7408-4697-8C8B-3D177303A76FQ47899720-7E139910-5F4B-458E-AF82-4079727C72A6Q50097989-5FD97F2F-0D4E-4056-B444-40CAAF87A32E
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Adam Searleman
@ast
Adam Searleman
@en
Adam Searleman
@es
Adam Searleman
@nl
type
label
Adam Searleman
@ast
Adam Searleman
@en
Adam Searleman
@es
Adam Searleman
@nl
prefLabel
Adam Searleman
@ast
Adam Searleman
@en
Adam Searleman
@es
Adam Searleman
@nl
P106
P1153
57193303897
P21
P31
P496
0000-0003-1084-2415